STXS

Stereotaxis, Inc. (STXS) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Stereotaxis, Inc. designs, manufactures, and markets robotic systems (Robotic Magnetic Navigation) and instruments for the interventional laboratory, primarily focusing on electrophysiology and cardiac ablation. The company completed the acquisition of Access Point Technologies EP, Inc. (APT) in July 2024, integrating catheter manufacturing capabilities. As of July 31, 2025, there were 90,653,769 shares of common stock outstanding.

Key Financial Metrics (Six Months Ended June 30, 2025)

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 43% year-over-year (YoY) to $16.3 million for the six months ended June 30, 2025, compared to $11.4 million in 2024. This was driven by a 75% increase in Systems revenue ($5.0M vs. $2.9M) and a 32% increase in Disposables/Service revenue ($11.3M vs. $8.5M), largely due to the inclusion of APT post-acquisition sales.
• Gross Margin Compression: Gross margin percentage decreased to 53% from 64% in the prior year period. Management attributes this to product mix changes and acquisition-related accounting adjustments requiring the valuation of acquired finished goods inventory at fair value.
• Operating Expenses: General and Administrative (G&A) expenses increased 18% YoY to $8.5 million, driven by amortization of acquisition-related intangible assets and a $0.5 million loss on the revaluation of contingent consideration. Research and Development (R&D) expenses decreased 9% to $4.1 million, primarily due to the capitalization of GenesisX development costs into inventory.
• Liquidity: Cash and cash equivalents decreased from $12.2 million at year-end 2024 to $7.0 million at June 30, 2025. Net cash used in operating activities was $5.5 million.

Guidance, Outlook, and Risks

• Regulatory Milestones: The GenesisX RMN System received CE Mark in Europe (Q3 2024) and is seeking FDA 510(k) clearance. The MAGiC Sweep catheter received FDA clearance in July 2025. The company is pursuing approvals for the EMAGIN 5F catheter guide.
• Capital Raise: In a subsequent event (July 2025), the company entered into a registered direct offering to sell $12.5 million of common stock. Initial proceeds of $8.5 million were received in July 2025, with an additional $4.0 million expected in November 2025.
• Tariff and Trade Risks: The company faces significant uncertainty regarding global tariffs. New U.S. tariffs on imports from China, Canada, and the EU, as well as steel/aluminum tariffs, could materially affect cost structures and gross margins. The company notes that while some sub-assemblies qualify for USMCA exemptions, specialty metals and raw materials from Europe and Japan are subject to baseline tariffs.
• Liquidity Outlook: Management expects to incur additional losses in 2025 as it continues product development and commercialization. While current cash plus the July 2025 equity raise is believed to be sufficient for operations, the company cannot guarantee it will not need additional funding in the future.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $7.0M cash balance plus the $12.5M equity raise against the burn rate of ~$5.5M per six months.
• System Sales Pipeline: Confirm the backlog of $12.2 million in remaining performance obligations for system contracts and the timeline for recognition.
• Tariff Impact: Assess the specific exposure of the supply chain to the new 10% baseline tariffs and potential 30% reciprocal tariffs on Chinese goods, particularly regarding the MAGiC catheter launch in the U.S.
• APT Integration: Monitor the realization of synergies from the APT acquisition and the impact of fair value adjustments on future gross margins.
• Contingent Consideration: Track the fair value revaluation of the $12.2M earnout liability, which impacts G&A expenses and net loss.